218 related articles for article (PubMed ID: 34554931)
1. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics.
Bekele RT; Samant AS; Nassar AH; So J; Garcia EP; Curran CR; Hwang JH; Mayhew DL; Nag A; Thorner AR; Börcsök J; Sztupinszki Z; Pan CX; Bellmunt J; Kwiatkowski DJ; Sonpavde GP; Van Allen EM; Mouw KW
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34554931
[TBL] [Abstract][Full Text] [Related]
2. RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma.
Clark-Garvey S; Kim WY
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779406
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
4. Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities.
Kawauchi K; Lazarus AH; Sanghera JS; Man GL; Pelech SL; Delovitch TL
Mol Immunol; 1996 Feb; 33(3):287-96. PubMed ID: 8649450
[TBL] [Abstract][Full Text] [Related]
5. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
6. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
7. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer.
Borovski T; Vellinga TT; Laoukili J; Santo EE; Fatrai S; van Schelven S; Verheem A; Marvin DL; Ubink I; Borel Rinkes IHM; Kranenburg O
Gut; 2017 Jun; 66(6):1106-1115. PubMed ID: 27670374
[TBL] [Abstract][Full Text] [Related]
9. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
10. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
[TBL] [Abstract][Full Text] [Related]
11. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
Noser JA; Mael AA; Sakuma R; Ohmine S; Marcato P; Lee PW; Ikeda Y
Mol Ther; 2007 Aug; 15(8):1531-6. PubMed ID: 17505473
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Zhuang S; Söderkvist P
Mutat Res; 2000 Jul; 452(1):19-26. PubMed ID: 10894886
[TBL] [Abstract][Full Text] [Related]
13. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract][Full Text] [Related]
14. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
[TBL] [Abstract][Full Text] [Related]
15. The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras.
Jaiswal RK; Moodie SA; Wolfman A; Landreth GE
Mol Cell Biol; 1994 Oct; 14(10):6944-53. PubMed ID: 7935411
[TBL] [Abstract][Full Text] [Related]
16. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
18. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
19. Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.
Mazalouskas MD; Godoy-Ruiz R; Weber DJ; Zimmer DB; Honkanen RE; Wadzinski BE
J Biol Chem; 2014 Feb; 289(7):4219-32. PubMed ID: 24371145
[TBL] [Abstract][Full Text] [Related]
20. RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα.
Varga A; Ehrenreiter K; Aschenbrenner B; Kocieniewski P; Kochanczyk M; Lipniacki T; Baccarini M
Sci Signal; 2017 Mar; 10(469):. PubMed ID: 28270557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
